Russian pharma sector ups production of vital and essential drugs despite sanctions

The volume of drug production in Russia is steadily growing this year despite the ever-tightening sanctions regime and international isolation of Russia, according to recent statements by some leading local pharma analysts and the Russian media, reports The Parma Letter’s local correspondent.

According to data of the Russian consulting agency the Center for the Development of Advanced Technologies (CRPT), since the beginning of the year, the production of almost 1000 various drugs has increased in Russia. In general, the growth of output for the reporting period amounted to 5% year-on-year basis.

According to CRPT analysts, today Russian pharmaceutical companies produce more than 1.600 types of various drugs. The biggest growth of output was observed in case of such drugs as acetylsalicylic acid + magnesium hydroxide, umifenovir, paracetamol, bromhexine and some others, while their domestic production already covers the local consumption.